SCHEMBL3877682

SCHEMBL3877682

CNCC#Cc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.41
SLC6A4 P31645 4/20 0.40
SLC6A3 Q01959 2/20 0.40
CYP2A6 P11509 1/20 0.40
CYP2C9 P11712 1/20 0.40
CHRNB2 P17787 1/20 0.40
CYP2B6 P20813 1/20 0.40
CYP2C19 P33261 1/20 0.40
CHRNA4 P43681 1/20 0.40
MAOB P27338 1/20 0.40
AOC3 Q16853 1/20 0.40
LMNA P02545 2/20 0.39
MAPT P10636 1/20 0.39
EPHX2 P34913 1/20 0.39
KIF11 P52732 1/20 0.37
POLB P06746 1/20 0.37
MRGPRX4 Q96LA9 1/20 0.37
CARM1 Q86X55 1/20 0.36
PRMT6 Q96LA8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16841023 0.82 ACACB (0.44) ACACBL3MBTL1SLC6A4SLC6A3MAOB
SCHEMBL28766882 0.80 ACACB (0.51) ACACBLMNAEPHX2POLBMRGPRX4
SCHEMBL28659226 0.79 ACACB (0.50) ACACBL3MBTL1MAOBAOC3MAPT
SCHEMBL1065335 0.79 ACACB (0.43) ACACBL3MBTL1SLC6A4SLC6A3MAOB
SCHEMBL80921 0.79 ACACB (0.46) ACACBL3MBTL1MAOBAOC3LMNA
SCHEMBL16298701 0.78 APP (0.52) ACACBL3MBTL1CYP2A6CYP2C9CHRNB2
SCHEMBL16922731 0.77 ACACB (0.42) ACACBL3MBTL1CYP2C9CYP2C19MAOB
SCHEMBL16922733 0.77 ACACB (0.42) ACACBL3MBTL1CYP2C9CYP2C19MAOB
SCHEMBL19599384 0.77 ACACB (0.42) ACACBMAOBAOC3KIF11
SCHEMBL19313723 0.77 ACACB (0.42) ACACBL3MBTL1CYP2C9CYP2C19MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101001837-B Indole derivatives comprising an acetylene group as PPAR activators HOFFMANN LA ROCHE 2012-11-07 CN disclosed
EP-1781608-B1 INDOLE DERIVATIVES COMPRISING AN ACETYLENE GROUP AS PPAR ACTIVATORS HOFFMANN LA ROCHE (CH) 2009-10-21 EP disclosed
US-7405236-B2 Indole derivatives comprising an acetylene group HOFFMAN-LA ROCHE INC. (US) 2008-07-29 US disclosed
CN-101001837-A Indole derivatives comprising an acetylene group as PPAR activators HOFFMANN LA ROCHE (CH) 2007-07-18 CN disclosed
EP-1781608-A1 INDOLE DERIVATIVES COMPRISING AN ACETYLENE GROUP AS PPAR ACTIVATORS F.HOFFMANN-LA ROCHE AG (CH) 2007-05-09 EP disclosed
WO-2006018174-A1 INDOLE DERIVATIVES COMPRISING AN ACETYLENE GROUP AS PPAR ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2006-02-23 WO disclosed
US-20060035956-A1 e.g. {6-[5-(4-trifluoromethoxy-phenyl)-pent-4-ynyloxy]-indol-1-yl}-acetic acid; peroxisome proliferator activated receptor PPAR delta or PPAR alpha agonist; antidiabetic, antiinflammatory agent, cardiovascular disorders; non-insulin dependent diabetes, insulin resistance, atherosclerosis HOFFMANN-LA ROCHE INC. 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035956-A1 e.g. {6-[5-(4-trifluoromethoxy-phenyl)-pent-4-ynyloxy]-indol-1-yl}-acetic acid; peroxisome proliferator activated receptor PPAR delta or PPAR alpha agonist; antidiabetic, antiinflammatory agent, cardiovascular disorders; non-insulin dependent diabetes, insulin resistance, atherosclerosis PPARD, PPARG, PPARA ACACB 461/4885L3MBTL1 3969/4885SLC6A4 4412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.